By James Heilman, MD

Bone Markers As Screening Strategy For Patient Adherence To Osteoporosis Medications

ArticlePress release
Bone, Muscle, & Joint
Laboratory Procedures
+1
Contributed byKrish Tangella MD, MBAFeb 13, 2017

Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication - a problem commonly seen with many chronic diseases - is a critical issue as it jeopardizes the efficacy of treatment, leaving osteoporosis patients unprotected against fractures.

A newly published International Osteoporosis Foundation (IOF) and European Calcified Tissue Society (ECTS) Working Group position paper [1] proposes measuring specific bone turnover markers (BTMs) in patients who have initiated use of oral bisphosphonates for postmenopausal osteoporosis as a clinically feasible and practical way to identify low adherence. BTMs can reflect the early effect of the drug on bone tissue. If a low response is detected shortly after treatment has been started, this can indicate low adherence or point to underlying causes of impaired response to medication.

Using the findings of the TRIO study [2] as the basis for their recommendations, the Working Group recommends measuring serum PINP (procollagen type 1 N-terminal propeptide) and CTX (collagen type 1 C-terminal telopeptide) levels at baseline and after 3 months of initiating treatment. The timing for the assessment at 3 months is optimal because the first weeks after the prescription is given is the critical period of primary non-adherence, when patients are most likely to have discontinued treatment.

The Working Group recommends that in those individuals where the decrease of the two BTMs, PINP and CTX does not exceed the least significant change (38% and 56%, respectively) assessment of adherence, or possibly investigation of secondary osteoporosis, should be carried out.

Professor Adolfo Diez-Perez, Co-Chair of the Joint IOF-ECTS Adherence Working Group, stated, "The use of bone turnover marker measurement to detect a lack of response to oral bisphosphonates is a practical and low-cost screening procedure which helps identify potential non-adherence in patients very early after treatment initiation. The patients benefit as this opens up opportunity for discussion and early intervention with noncompliant patients, or can indicate that secondary causes of osteoporosis need to be assessed."

Co-Chair of the Working Group, Professor Richard Eastell, emphasized that "It will be interesting to further evaluate if these recommendations have an impact on adherence in a real-life setting."


Materials provided by International Osteoporosis FoundationNote: Content may be edited for style and length.

Disclaimer: DoveMed is not responsible for the accuracy of the adapted version of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

Diez-Perez, A., Naylor, K. E., Abrahamsen, B., Agnusdei, D., Brandi, M. L., Cooper, C., ... & Hadji, P. (2017). International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 1-8. DOI: 10.1007/s00198-017-3906-6

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!